Direct hemoperfusion with polymyxin B-immobilized fibre treatment for acute exacerbation of interstitial pneumonia

Respirology ◽  
2017 ◽  
Vol 22 (7) ◽  
pp. 1357-1362 ◽  
Author(s):  
Haruhiko Furusawa ◽  
Makiko Sugiura ◽  
Chieko Mitaka ◽  
Naohiko Inase
Keyword(s):  
Acute Exacerbation ◽  
Interstitial Pneumonia ◽  
Polymyxin B ◽  
Direct Hemoperfusion ◽  
Fibre Treatment

scholarly journals Early initiation of direct hemoperfusion with a polymyxin B-immobilized fiber column for the acute exacerbation of interstitial pneumonia

2017 ◽  
Vol 50 (10) ◽  
pp. 607-614
Author(s):  
Masamitsu Ubukata ◽  
Masaki Hara ◽  
Kumiko Momoki ◽  
Kosaku Nitta ◽  
Akihito Ohta
Keyword(s):  
Acute Exacerbation ◽  
Interstitial Pneumonia ◽  
Polymyxin B ◽  
Early Initiation ◽  
Direct Hemoperfusion

scholarly journals Serum Lactate Dehydrogenase Level As a Predictor Of Survival For Patients With Acute Exacerbation of Idiopathic Interstitial Pneumonias Undergoing Polymyxin B-Immobilized Fiber Column-Direct Hemoperfusion

2021 ◽  
Author(s):  
Motoyasu Kato ◽  
Shun Nakazawa ◽  
Takashi Akimoto ◽  
Soichiro Soma ◽  
Hayakawa Eri ◽  
...  
Keyword(s):  
Lactate Dehydrogenase ◽  
Acute Exacerbation ◽  
Poor Prognosis ◽  
Polymyxin B ◽  
Serum Marker ◽  
Serum Markers ◽  
Serum Lactate ◽  
Serum Lactate Dehydrogenase ◽  
Survival Group ◽  
Direct Hemoperfusion

Abstract BackgroundAcute exacerbation of chronic fibrosing idiopathic interstitial pneumonias (AE-IIPs) is known to be associated with a poor prognosis. In Japan, polymyxin B-immobilized fiber column-direct hemoperfusion (PMX-DHP) therapy is often used along with corticosteroids for the treatment of patients with AE-IIPs. However, the serum marker that predicts treatment response to PMX-DHP is still unknown. Our aim was to evaluate the serum marker that predicts the outcome in patients with AE-IIPs undergoing PMX-DHP therapy.MethodsWe retrospectively collected the medical records of 104 patients who developed AE-IIPs for the first time and visited Juntendo University Hospital between April 2009 and July 2020. Among these patients, 33 patients who received PMX-DHP were identified. Among the patients who received PMX-DHP, 18 patients who survived for over 30 days since the initiation of PMX-DHP therapy were classified into the “survival group,” and 15 patients who succumbed to the condition in less than 30 days were categorized into the “non-survival group.” We evaluated data on the patients’ background, survival, and differences in the serum markers associated with AE-IIPs and in oxygenation markers between the groups.ResultsAmong patient characteristics, median forced vital capacity was significantly higher in the survival group than in the non-survival group. Among serum markers, 7 days after the initiation of PMX-DHP therapy, serum lactate dehydrogenase (LDH) levels, white blood cell counts, and D-dimer levels were significantly higher and serum lymphocyte count was significantly lower in the non-survival group than in the survival group. PaO2/FiO2 ratio (P/F ratio) and alveolar-arterial oxygen difference (Aa-DO2) were significantly different between the two groups. The changes in LDH level (ΔLDH), P/F ratio, and Aa-DO2 were significantly different from day 1 to 7 days after the initiation of PMX-DHP between the two groups. Multivariate analysis revealed that ΔLDH was the only risk factor associated with poor prognosis. The cut-off value of ΔLDH was calculated as −8. The median survival time (MST) was significantly longer in patients with low ΔLDH values (<−8) than in those with high ΔLDH values (>−8).ConclusionsChanges in serum LDH levels are reasonable markers for evaluating the prognosis of PMX-DHP therapy.

scholarly journals Direct hemoperfusion with polymyxin B-immobilized fiber column in a patient with acute exacerbation of idiopathic pulmonary fibrosis

2020 ◽  
Vol 35 (4) ◽  
pp. 302-306
Author(s):  
Shin Young Kim ◽  
Jin Han Park ◽  
Hyo Jung Kim ◽  
Hang Jea Jang ◽  
Hyun Kuk Kim ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Acute Exacerbation ◽  
Polymyxin B ◽  
Direct Hemoperfusion

scholarly journals Two Cases of Acute Exacerbation of Interstitial Pneumonia Treated with Polymyxin B-immobilized Fiber Column Hemoperfusion Treatment

2007 ◽  
Vol 46 (17) ◽  
pp. 1447-1454 ◽  
Author(s):  
Satoshi Noma ◽  
Wataru Matsuyama ◽  
Hideo Mitsuyama ◽  
Takayuki Suetsugu ◽  
Yoshimizu Koreeda ◽  
...  
Keyword(s):  
Acute Exacerbation ◽  
Interstitial Pneumonia ◽  
Polymyxin B

Evaluation of Different Perfusion Durations in Direct Hemoperfusion with Polymyxin B-Immobilized Fiber Column Therapy for Acute Exacerbation of Interstitial Pneumonias

2011 ◽  
Vol 32 (2) ◽  
pp. 75-81 ◽  
Author(s):  
Masato Kono ◽  
Takafumi Suda ◽  
Noriyuki Enomoto ◽  
Yutaro Nakamura ◽  
Yusuke Kaida ◽  
...  
Keyword(s):  
Acute Exacerbation ◽  
Polymyxin B ◽  
Direct Hemoperfusion
Sign in / Sign up

Export Citation Format

Share Document